Amlodipine (Dihydropyridine CCB)
Treatment for Hypertensive heart disease
Typical Dosage: 2.5mg - 10mg daily
Effectiveness
86%
Safety Score
70%
Clinical Trials
2
Participants
800K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
70
DangerousModerateSafe
Treatment Details
Dosage Range
2.5mg - 10mg daily
Time to Effect
1-2 weeks for full BP effect, months for cardiac remodeling
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
20(Treat 20 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
94%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$40
Monitoring:$300
Side Effect Mgmt:$75
Total Annual:$415
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$22,000/QALY
QALYs Gained
2.3
Outcome-Based Costs
Cost per Responder
$532.05
Comparison vs Lisinopril (ACE Inhibitor)
Cost Difference
+$10/year
More expensive
QALY Difference
0.00 QALYs
Same outcomes
Dominance
No dominance
Amlodipine (Dihydropyridine CCB) Outcomes
for Hypertensive heart disease
Efficacy Outcomes
Overall Effectiveness
+86%
Response Rate
+78%
Common Side Effects
Peripheral edema
+15%
Headache
+8%
Flushing
+5%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
2 completed trials for Amlodipine (Dihydropyridine CCB) in Hypertensive heart disease
Azelnidipine Anti-Coronary Atherosclerotic Trial in Hypertensive Patients by Serial Volumetric IVUS Analysis(ALPS-J)
NCT00294567COMPLETEDPHASE4
199 participants
INTERVENTIONAL
Tokyo, Japan
Started: Dec 1, 2005
Comparison of Valsartan With Amlodipine in Hypertensive Patients With Glucose Intolerance
NCT00129233COMPLETEDPHASE4
1.15K participants
INTERVENTIONAL
Nagoya, Japan
Started: Oct 1, 2004